First patient dosed in GE HealthCare’s Phase II/III LUMINA clinical trial
Summary
GE HealthCare has dosed the first patient in its Phase II/III LUMINA clinical trial for the investigational manganese-based MRI contrast agent, mangaciclanol.
Description
GE HealthCare has dosed the first patient in its Phase II/III LUMINA clinical trial for the investigational manganese-based MRI contrast agent, mangaciclanol.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source